{
  "id": "transplant-rejection",
  "title": "Transplant Rejection",
  "lang": "en",
  "source_lang": "en",
  "summary": "Transplant rejection is an immune response against transplanted cells, tissues, or organs that can damage the graft and impair its function.",
  "category": "health",
  "subcategory": "medicine",
  "type": "concept",
  "aliases": [
    "Graft rejection",
    "Allograft rejection"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/transplant-rejection/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/transplant-rejection/",
      "json": "https://aiwiki.page/zh/transplant-rejection.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Transplant rejection is an immune response in which a recipient’s immune system recognizes transplanted cells, tissues, or organs as foreign and attacks them. It is a major complication of organ transplantation and can cause reversible injury, progressive loss of function, or graft failure. Rejection is classified by its underlying immune mechanisms and patterns of tissue injury, not simply by the time elapsed since transplantation. Modern compatibility testing and immunosuppression have reduced its frequency, but rejection remains possible throughout the life of a transplant."
    },
    {
      "heading": "Immunological basis",
      "text": "Most transplanted organs are allografts: grafts transferred between genetically different members of the same species. The recipient’s immune system can recognize differences between donor and recipient, particularly differences in human leukocyte antigen (HLA) molecules. These cell-surface proteins present peptide fragments to immune cells and are central to distinguishing self from foreign tissue.\n\nRecognition of donor antigens, called allorecognition, activates several interacting pathways:\n\n- Cell-mediated injury: recipient T cells recognize donor antigens, release inflammatory signals, recruit other immune cells, and injure graft cells.\n- Antibody-mediated injury: recipient antibodies bind targets on the graft, particularly the lining of its blood vessels. They can activate the complement system and other mechanisms that damage the microcirculation.\n- Amplification by inflammation: tissue injury associated with organ retrieval, preservation, and restoration of blood flow can promote inflammation and strengthen the subsequent immune response.\n\nDonor-reactive antibodies may already be present before transplantation or develop afterward. Previous transplantation, blood transfusion, and pregnancy can expose a person to foreign HLA antigens and lead to sensitization. Antibodies against ABO blood-group antigens can also be important in some transplant settings."
    },
    {
      "heading": "Main forms",
      "text": "The traditional categories—hyperacute, acute, and chronic rejection—describe characteristic clinical and pathological patterns. They overlap with mechanistic categories such as T-cell-mediated rejection and antibody-mediated rejection.\n\nHyperacute rejection\n\nHyperacute rejection usually develops within minutes to hours after blood flow is established in a graft. It results from pre-existing recipient antibodies directed against donor antigens, commonly HLA or ABO antigens.\n\nAntibody binding can produce widespread vascular injury, thrombosis, and rapid loss of graft function. Hyperacute rejection has become uncommon in standard clinical transplantation because blood-group compatibility assessment, antibody testing, and transplant crossmatching identify many high-risk donor–recipient combinations before transplantation.\n\nAcute T-cell-mediated rejection\n\nAcute T-cell-mediated rejection involves activated recipient T cells and associated inflammatory cells entering and damaging graft tissue. It often occurs during the early months after transplantation but can also arise years later, particularly when effective immunosuppression is reduced.\n\nThe affected structures vary by organ. In kidney grafts, characteristic lesions include inflammation of the interstitial tissue and tubules, sometimes with arterial involvement. Other transplanted organs have their own diagnostic patterns and grading systems.\n\nMany episodes respond to treatment, but severe or recurrent episodes can contribute to lasting injury.\n\nAntibody-mediated rejection\n\nAntibody-mediated rejection is associated with antibodies directed against donor antigens, often called donor-specific antibodies. These antibodies may be present at transplantation or emerge later.\n\nDiagnosis generally integrates evidence of graft injury, evidence of antibody interaction with the graft, and antibody testing. In kidney transplantation, microvascular inflammation and deposition of the complement fragment C4d can support the diagnosis. However, C4d is not present in every case, and donor-specific antibodies alone do not establish that active rejection is occurring.\n\nAntibody-mediated rejection can be acute or chronic active. It may coexist with T-cell-mediated rejection.\n\nChronic rejection and chronic active injury\n\nChronic rejection involves persistent or recurrent immune injury accompanied by structural changes that accumulate over time. Depending on the organ, these may include narrowing of graft vessels, loss of small bile ducts, small-airway damage, and fibrosis.\n\nTerminology differs across transplant specialties. Chronic active antibody-mediated rejection is an important category in kidney transplantation, while cardiac allograft vasculopathy is a major manifestation of long-term immune-associated vascular injury in heart transplantation.\n\nChronic graft dysfunction is not synonymous with chronic rejection. Drug toxicity, infection, recurrent disease, vascular disease, and other nonimmune processes can also cause progressive transplant failure."
    },
    {
      "heading": "Clinical manifestations and diagnosis",
      "text": "Rejection may cause no noticeable symptoms, especially early in its course. Routine surveillance can therefore detect graft injury before symptoms appear. When manifestations occur, they depend on the transplanted organ and may include changes in urine production, breathlessness, abnormal liver tests, or impaired cardiac function. Fever and graft discomfort are possible but neither necessary nor specific.\n\nAssessment combines several types of evidence:\n\n- Functional measurements: for example, creatinine and estimated filtration rate after kidney transplantation, liver blood tests after liver transplantation, or lung-function measurements after lung transplantation.\n- Immunological testing: particularly testing for donor-specific antibodies.\n- Imaging: often used to investigate vascular, obstructive, or surgical causes of graft dysfunction.\n- Tissue examination: biopsy and histopathology remain central to diagnosing and classifying many forms of rejection.\n\nKidney transplant biopsies are commonly assessed using the Banff classification, an international framework that integrates tissue findings with relevant immunological and molecular evidence. Other organs use organ-specific classification systems.\n\nNewer biomarkers, including donor-derived cell-free DNA and gene-expression tests, can support assessment in selected transplant settings. Their interpretation depends on the organ, test, and clinical context; they do not universally replace biopsy.\n\nThe differential diagnosis includes infection, inadequate blood supply, urinary or biliary obstruction, medication toxicity, and recurrence of the recipient’s original disease. These conditions may coexist with rejection."
    },
    {
      "heading": "Prevention and treatment",
      "text": "Prevention combines donor–recipient compatibility assessment, evaluation of pre-existing antibodies, and immunosuppressive medication. HLA matching has particular importance in kidney transplantation, although its role and practical use differ among organs.\n\nMaintenance regimens commonly combine medicines acting at different points in the immune response. These may include a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Some recipients also receive antibody-based induction treatment around the time of transplantation. Drug selection and intensity vary according to the transplanted organ, immunological risk, and adverse effects.\n\nTreatment depends on the mechanism and severity of rejection:\n\n- T-cell-mediated rejection is often treated with corticosteroids; more severe or resistant episodes may require T-cell-depleting treatment.\n- Antibody-mediated rejection may be treated with combinations intended to remove antibodies or modify antibody production and associated immune activity. Approaches include plasma exchange and intravenous immunoglobulin, with additional agents used in selected circumstances.\n- Established chronic scarring is generally not reversible. Treatment focuses on controlling ongoing immune injury and addressing other contributors to graft dysfunction.\n\nEvidence for treatment is uneven across rejection subtypes, particularly chronic active antibody-mediated rejection. No single regimen reliably reverses all forms.\n\nImmunosuppression also has substantial risks, including opportunistic infections, medication toxicity, metabolic complications, and some cancers. Clinical management therefore balances suppression of graft-directed immunity against these harms."
    },
    {
      "heading": "Distinction from graft-versus-host disease",
      "text": "Transplant rejection usually involves the recipient’s immune system attacking the graft. In graft-versus-host disease, immune cells transferred with the graft attack the recipient’s tissues. The latter is particularly associated with hematopoietic stem-cell transplantation, although it can occur after certain solid-organ transplants.\n\nIn stem-cell transplantation, rejection can contribute to graft failure, but graft failure also has other causes and is not interchangeable with graft-versus-host disease."
    },
    {
      "heading": "Consequences and variation among organs",
      "text": "Outcomes depend on the organ, rejection mechanism, severity, timing of detection, response to treatment, and extent of pre-existing damage. An episode of rejection does not necessarily mean that a transplant will fail. Conversely, low-grade or clinically silent immune injury may accumulate and reduce long-term graft survival.\n\nTransplanted organs differ in their susceptibility to rejection and in how rejection is detected. The liver has distinctive immune properties and can sometimes tolerate lower immunosuppressive exposure than other solid organs, but it remains susceptible to serious rejection. Across transplant types, graft function, biopsy findings, antibody results, and other clinical information are interpreted together rather than treating any single abnormal result as definitive."
    }
  ],
  "links": [
    "immune-system",
    "organ-transplantation",
    "immunosuppression",
    "human-leukocyte-antigen",
    "t-cell",
    "antibody",
    "complement-system",
    "inflammation",
    "blood-transfusion",
    "pregnancy",
    "thrombosis",
    "transplant-crossmatch",
    "fibrosis",
    "biopsy",
    "histopathology",
    "biomarker",
    "differential-diagnosis",
    "corticosteroid",
    "opportunistic-infection",
    "cancer",
    "graft-versus-host-disease",
    "hematopoietic-stem-cell-transplantation"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}